Akebia Therapeutics, Inc. Announces Presentation Of AKB-6548 Phase 2b Data At The 52nd ERA-EDTA Annual Congress

MBRIDGE,Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that data from its Phase 2b trial of AKB-6548 in non-dialysis patients with anemia related to chronic kidney disease will be featured in an oral presentation at the 2015 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 52nd Congress, which is being held in London from May 28 - May 31, 2015.

Help employers find you! Check out all the jobs and post your resume.

Back to news